A 72.2% confirmed objective response rate against a 43.2% standard-of-care benchmark is not a modest signal — it is a 29-percentage-point gap in a disease, RAS-mutated metastatic colorectal cancer, where first-line options have barely moved in years. Cardiff Oncology’s Phase 2 CRDF-004 data for onvansertib plus FOLFIRI/bevacizumab also produced a progression-free survival hazard ratio of 0.37 versus the combined standard-of-care arms, with statistical significance, and without a meaningful toxicity penalty. That combination — magnitude, durability, and tolerability — is what earns a productive End-of-Phase 2 FDA meeting, and Cardiff got one in April.
The FDA alignment locked in the 30 mg onvansertib dose paired specifically with FOLFIRI/bev as the Phase 3 regimen, not FOLFOX/bev. That distinction matters. CRDF-004 tested both backbone chemotherapies, but only the FOLFIRI arm generated the compelling PFS separation. The Phase 3 design is therefore built around the arm that performed, rather than a composite of the trial’s activity — a disciplined and defensible regulatory choice. Full trial design details are expected by mid-2026, and the ASCO rapid oral presentation at the end of May will deliver updated CRDF-004 data that will sharpen the picture of durability and subgroup consistency before that Phase 3 blueprint goes public.
The financial picture introduces real urgency. With $46.1 million in cash and a quarterly burn rate of approximately $12.3 million, Cardiff’s runway extends only into Q1 2027 — meaning Phase 3 initiation almost certainly requires a capital raise before enrollment can meaningfully scale. The company reduced R&D spending by $3.7 million year-over-year, but SG&A rose $2.1 million partly from severance costs tied to the leadership transition, which absorbed most of those savings. The new executive team — CEO Mani Mohindru now confirmed permanent, a new CFO, and a new COO — took shape in April, just as the FDA meeting concluded. That timing is deliberate: the leadership infrastructure is being built to support a financing event and a Phase 3 launch in close succession.
The single number to watch coming out of ASCO is median PFS in the 30 mg FOLFIRI/bev arm. The hazard ratio is compelling, but the absolute duration of that benefit will determine how aggressively investors price a Phase 3 and how urgently Cardiff needs to move on its next financing round.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
